Delaware
|
001-11460
|
31-1103425
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
140 58th Street, Building A, Suite 2100
|
||
Brooklyn, New York
|
11220
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
Common Stock, $0.005 par value per share
|
BTX
|
NYSE American
|
Item 1.01. |
Entry into a Material Definitive Agreement.
|
• |
extend the exercise period for the Option from April 30, 2021 to May 21, 2021; and
|
• |
require that Brooklyn LLC pay a total of $1.0 million of the initial license fees to the Licensors by April 15, 2021, which amount has been paid by Brooklyn LLC and will be refundable
by the Licensors if Brooklyn LLC does not exercise the Option by May 21, 2021.
|
BROOKLYN IMMUNOTHERAPEUTICS, INC.
|
||
By:
|
/s/ Ronald Guido
|
|
Ronald Guido
|
||
Interim Chief Executive Officer and
|
||
Chief Development Officer
|
||
Dated: April 15, 2021
|